| __timestamp | Halozyme Therapeutics, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 13673000 |
| Thursday, January 1, 2015 | 93236000 | 14358000 |
| Friday, January 1, 2016 | 150842000 | 12203000 |
| Sunday, January 1, 2017 | 150643000 | 18125000 |
| Monday, January 1, 2018 | 150252000 | 17071000 |
| Tuesday, January 1, 2019 | 140804000 | 20018000 |
| Wednesday, January 1, 2020 | 34236000 | 32788000 |
| Friday, January 1, 2021 | 35672000 | 44966000 |
| Saturday, January 1, 2022 | 66607000 | 311681000 |
| Sunday, January 1, 2023 | 76363000 | 77707000 |
Data in motion
In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal for innovation and growth. Over the past decade, Halozyme Therapeutics, Inc. and Lantheus Holdings, Inc. have demonstrated contrasting R&D strategies.
From 2014 to 2023, Halozyme's R&D expenses fluctuated, peaking in 2016 and 2017 with investments over 150% higher than their 2020 low. This strategic shift reflects a focus on optimizing resources while maintaining a robust pipeline.
Conversely, Lantheus Holdings has shown a remarkable upward trend, with R&D spending in 2022 surging by over 2000% compared to 2014. This aggressive investment underscores their commitment to expanding their portfolio and enhancing technological capabilities.
As these companies navigate the competitive biotech sector, their R&D strategies will continue to shape their future trajectories.
Eli Lilly and Company vs Lantheus Holdings, Inc.: Strategic Focus on R&D Spending
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Sanofi and Lantheus Holdings, Inc.
GSK plc or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
argenx SE vs Halozyme Therapeutics, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Incyte Corporation vs Halozyme Therapeutics, Inc.
R&D Insights: How Summit Therapeutics Inc. and Halozyme Therapeutics, Inc. Allocate Funds
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Research and Development Investment: Halozyme Therapeutics, Inc. vs PTC Therapeutics, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs Veracyte, Inc.
Blueprint Medicines Corporation or Lantheus Holdings, Inc.: Who Invests More in Innovation?
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending